Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT05924321 · ClinicalTrials.gov registry record · Phase 1
A Study to Evaluate the Effect of Carbetocin on the QT/QTc Interval in Healthy Subjects
A Phase 1 study of Postpartum Hemorrhage, sponsored by Ferring Pharmaceuticals.
- Completed
- Registry status
- Phase 1
- Development phase
- 40
- Enrollment target
- 1
- Study location
NCT05924321: Completed Phase 1 study of Postpartum Hemorrhage, sponsored by Ferring Pharmaceuticals.
NCT05924321 is a Phase 1 study of Postpartum Hemorrhage that has completed, run by Ferring Pharmaceuticals. The registered enrollment target is 40 participants, below the 778-participant average among 19 other Postpartum Hemorrhage trials with a reported enrollment target (95% lower). The trial reports 1 study location across 1 state. According to ClinicalTrials.gov, the official US trial registry.
The verdict
NCT05924321, a Phase 1 study of Postpartum Hemorrhage, has completed, sponsored by Ferring Pharmaceuticals.
- COMPLETED
- Registry status
- Phase 1
- Development phase
- 40 participants
- Enrollment target
- 1
- Study location
Study Summary
Carbetocin is an oxytocin receptor agonist that selectively binds to receptors in the smooth muscle of the uterus, stimulates rhythmic contractions of the uterus, increases the frequency of existing contractions, and raises the tone of the uterine musculature. Carbetocin is approved in \>100 countries for the prevention of postpartum hemorrhage due to uterine atony in women following cesarean or vaginal delivery. Per regulatory requirements, the current trial will evaluate the effects of high clinical exposure of carbetocin on the QT interval corrected for heart rate (QTc) as measured by ECG in healthy men and women.
Primary Outcome
Part A
Conditions Studied
Interventions
- DRUG Placebo
- DRUG Carbetocin
- DRUG Placebo and Moxifloxacin
Study Locations (1)
Arizona
- Ferring Investigational Site - Tempe
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 40 participants |
| Start Date | 2023-05-25 |
| Est. Completion | 2023-09-21 |
| Phase | Phase 1 |
What the finished NCT05924321 record still lists
NCT05924321 is an interventional study that assigns participants to a tested intervention. The registry caps enrollment at 40 participants, a relatively small participant target, below the 778-participant average among 19 other Postpartum Hemorrhage trials with a reported enrollment target (95% lower).
The record links to 1 condition, with Postpartum Hemorrhage appearing as the primary indexed condition, and to 3 interventions - of which Placebo is the first listed.
NCT05924321 reports a single indexed study location in Arizona.
Frequently Asked Questions
What is clinical trial NCT05924321 about?
NCT05924321 is a clinical study titled "A Study to Evaluate the Effect of Carbetocin on the QT/QTc Interval in Healthy Subjects". Carbetocin is an oxytocin receptor agonist that selectively binds to receptors in the smooth muscle of the uterus, stimulates rhythmic contractions of the uterus, increases the frequency of existing contractions, and raises the tone of the uterine musculature. Carbetocin is approved in \>100 countri...
What is the current status of trial NCT05924321?
This trial is currently completed. It is a Phase 1 study. The enrollment target is 40 participants. The study started on 2023-05-25. Estimated completion is 2023-09-21.
What conditions does trial NCT05924321 study?
This clinical trial studies the following conditions: Postpartum Hemorrhage.
What interventions are being tested in trial NCT05924321?
The interventions under investigation include: Placebo (DRUG), Carbetocin (DRUG), Placebo and Moxifloxacin (DRUG).
Who is sponsoring clinical trial NCT05924321?
This trial is sponsored by Ferring Pharmaceuticals, which has 83 total clinical trials registered on ClinicalTrials.gov.
Where is trial NCT05924321 being conducted?
This trial has 1 study location across Arizona. Contact the study sites directly through ClinicalTrials.gov for enrollment availability.
Learn More About Clinical Trials
Similar trials for Postpartum Hemorrhage
Matched on the same primary condition, ranked to surface studies in the same phase first, then by recruiting status, no relevance scoring or editorial curation.
Where NCT05924321's enrollment target sits among peer trials
40 17th of 19 higher than 3 of 19 other Postpartum Hemorrhage trials
participants (enrollment target), bucketed by value
Each bar is a band; taller bars hold more other Postpartum Hemorrhage trials. The dashed line + filled bar mark this entry. Hover or tap any bar for its full count and share, and where it sits relative to this entry.
Source ClinicalTrials.gov registry export · 2026-08-08
-
Safety and Effectiveness of the KOKO Device to Treat Primary Abnormal Postpartum Uterine Bleeding or Hemorrhage
RECRUITING · NA
-
Double Simultaneous Uterotonic Agents Versus Single Agent Regimen to Prevent Early Postpartum Hemorrhage
RECRUITING · Phase 3
-
Oxytocin Pharmacokinetics and Pharmacodynamics
RECRUITING · Phase 2
-
A Pragmatic Randomized Controlled Trial to Predict Postpartum Hemorrhage
RECRUITING · NA
-
Prevention of Postpartum Hemorrhage With Tranexamic Acid
RECRUITING · Phase 2
-
Postpartum Ultrasound Evaluation to Assess Risk of Hemorrhage
RECRUITING
Nationwide trials with similar profiles
Cross-condition peers matched on enrollment target and registry start date, not the same-condition list above.
Similar enrollment target
- NCT01306019 · 40 participants · Phase 1
Lentiviral Gene Transfer for Treatment of Children Older Than Two Years of Age With X-Linked Severe Combined Immunodeficiency (XSCID)
- NCT01608152 · 40 participants
Development of a Video Game for the Improvement of Outcomes in Stem Cell Transplant Survivors
- NCT01668082 · 40 participants · NA
An Investigation of Brain Tumor Metabolism in Patients Undergoing Surgical Resection
- NCT02015013 · 40 participants · Phase 2
Hematopoietic Stem Cell Mobilization in Idiopathic CD4 Lymphocytopenia Patients and Healthy Controls for the Study of T Cell Maturation and Trafficking in Murine Models
Similar registry start date
- NCT05962346 · started 2026-12 · NA
Fetal Endoscopic Tracheal Occlusion for Congenital Diaphragmatic Hernia
- NCT07125183 · started 2026-12 · Phase 2
Study on Efficacy and Tolerability of Weekly Doxorubicin in Elderly Patients With Advanced or Metastatic Leiomyosarcoma
- NCT07292298 · started 2026-11 · Phase 2
Phase 2 Single-Arm Rectal Cancer Brachytherapy for Patients With Low-Lying Residual Adenocarcinoma After Total Neoadjuvant Therapy to Improve Organ Preservation Rates
- NCT04263285 · started 2026-10 · NA
Treatment of Depression Post-SCI